Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Consolati

Internal Medicine Lee, MA Medical Doctor

NPI 1326006362 CMS profile 14362

710 Stockbridge Rd, Lee, MA 01238

Open in the dashboard

General payments

$4,954

252 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Consolati of Lee, MA is reported in the CMS Open Payments database as having received $4,954 across 252 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $914 40
2024 General $726 28
2023 General $977 37
2022 General $562 28
2021 General $723 49
2020 General $440 29
2019 General $611 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Consolati
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Thomas Consolati were reported at $914. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Thomas Consolati Internal Medicine median Middle half National median
2019 $611 $159 $48–$570 $163
2020 $440 $119 $33–$402 $114
2021 $723 $135 $37–$521 $132
2022 $562 $141 $42–$496 $149
2023 $977 $149 $45–$519 $160
2024 $726 $154 $47–$537 $164
2025 $914 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $529 32 payments
  2. GlaxoSmithKline, LLC. $526 45 payments
  3. Neurocrine Biosciences, Inc. $504 6 payments
  4. AstraZeneca Pharmaceuticals LP $368 20 payments
  5. Janssen Pharmaceuticals, Inc $286 14 payments
  6. Merck Sharp & Dohme Corporation $276 17 payments
  7. Astellas Pharma US Inc $262 13 payments
  8. Lilly USA, LLC $248 12 payments
  9. Novo Nordisk Inc $183 10 payments
  10. AbbVie, Inc. $176 8 payments
  11. Other $1,595 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,931 250 payments
  2. Education $23 2 payments
Products named General payments · program years 2019–2025
  1. INGREZZA $504 6 payments
  2. TRELEGY ELLIPTA $377 31 payments
  3. ELIQUIS $255 16 payments
  4. MYRBETRIQ $185 9 payments
  5. Ozempic $168 9 payments
  6. ZENPEP $164 7 payments
  7. SPRAVATO $153 5 payments
  8. RYBELSUS $145 8 payments
  9. GEMTESA $136 5 payments
  10. XARELTO $133 9 payments
  11. Other $4,290 247 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 245 drugs

Part D claims

21,958

Median for Internal Medicine: 777

Drug cost

$1,867,390

Median for Internal Medicine: $73,373

Branded share of claims

21.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 957 $462,712
Humira Pen Adalimumab Brand 21 $154,917
Xarelto Rivaroxaban Brand 222 $141,731
Jardiance Empagliflozin Brand 152 $97,541
Januvia Sitagliptin Phosphate Brand 155 $90,751
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 158 $88,623
Abrysvo Rsv Vacc, Pref A And Pref B/Pf Brand 189 $60,544
Farxiga Dapagliflozin Propanediol Brand 96 $58,149
Ozempic Semaglutide Brand 39 $58,002
Trulicity Dulaglutide Brand 35 $50,392

The 10 drugs with the highest cost, of 245 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$286,623

Of which drugs: $17,928

Medicare patients

1,092

Average age 79

Services billed

4,996

574 women, 518 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 50%
Ischemic heart disease 32%
Depression 32%
Diabetes 28%
Atrial fibrillation 28%
Heart failure 27%
Osteoporosis 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 137 137 $11,180
Pcv20 vaccine im 90677 Office 22 22 $6,407

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $203
$203 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $50
  • Lundbeck LLC $24
$74 — —
MOUNJARO
  • Lilly USA, LLC $40
$40 17 —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $35
$35 — —
ZEPBOUND
  • Lilly USA, LLC $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record